(Q38175855)

English

Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus

scientific article published on February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

author name string

Sandeep Dhindsa

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Ishwarlal Jialal

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

publication date

1 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Current diabetes report

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

463

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

https://scigraph.springernature.com/pub.10.1007/s11892-013-0463-z

0 references

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Cardiovascular effects of the DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Cardiovascular effects of gliptins

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

The pathologic continuum of diabetic vascular disease

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

DPP-4 inhibitors and atherosclerosis: the promise

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Diabetes is a proinflammatory state: a translational perspective

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Sitagliptin exerts an antinflammatory action

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Exenatide exerts a potent antiinflammatory effect

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Imaging biomarkers in atherosclerosis trials

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Cardiovascular biology of the incretin system

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0463-Z

21 January 2018

Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

1 reference

https://pubmed.ncbi.nlm.nih.gov/24390468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24390468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dysfunctional endothelial progenitor cells in metabolic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24390468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from the REPERATOR study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24390468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating versus cellular biomarkers of inflammation in Type 1 diabetes: the superiority of C-reactive protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/24390468

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11892-013-0463-Z

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38175855&oldid=2091755154"